Keros Therapeutics Appoints Anne Prener to its Board of Directors
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Anne Prener to its Board of Directors effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience, expected to support Keros in advancing its therapeutic pipeline focused on TGF-beta family protein sign…